Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Down 77.2% in May

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 3,275 shares, a decline of 77.2% from the May 14th total of 14,337 shares. Based on an average trading volume of 21,621 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the company are sold short.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC lifted its stake in Barinthus Biotherapeutics by 115.8% in the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after buying an additional 76,800 shares in the last quarter. Rangeley Capital LLC increased its position in Barinthus Biotherapeutics by 88.8% during the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock worth $91,000 after purchasing an additional 75,024 shares in the last quarter. Finally, Baird Financial Group Inc. increased its position in Barinthus Biotherapeutics by 108.2% during the 2nd quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after purchasing an additional 100,000 shares in the last quarter. 25.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Barinthus Biotherapeutics has a consensus rating of “Hold” and a consensus price target of $4.00.

Barinthus Biotherapeutics Trading Up 0.6%

Shares of Barinthus Biotherapeutics stock opened at $0.72 on Wednesday. Barinthus Biotherapeutics has a 12-month low of $0.51 and a 12-month high of $2.92. The stock has a market cap of $29.58 million, a PE ratio of -0.56 and a beta of -0.40. The company has a 50-day moving average of $0.64 and a two-hundred day moving average of $0.67.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its earnings results on Thursday, April 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.14.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.